Retatrutide
phase3Triple GLP-1/GIP/glucagon receptor agonist — the most potent weight loss peptide in clinical trials
Availability in Thailand
Research-grade retatrutide is available from peptide vendors in Thailand with domestic shipping. It is not yet offered at mainstream clinics or hospitals, as it remains an investigational compound in Phase 3 clinical trials worldwide. Some boutique wellness clinics may include it in custom protocols — enquire directly.
Prescription: Not applicable — available as a research peptide from vendors without prescription.
Legal status: Not a controlled substance in Thailand. Available as a research chemical. Not approved for therapeutic use in any country.
⚠️ As an investigational compound, quality depends entirely on the vendor. Always verify third-party COA documentation before purchasing.
Where to Buy in Thailand
Research-grade retatrutide pricing varies by vendor and vial size. Check vendor websites for current rates as prices fluctuate with supply.
Vendors
Clinics
Overview
Retatrutide is a triple-hormone receptor agonist that simultaneously activates GIP, GLP-1, and glucagon receptors. This triple mechanism adds an energy expenditure component (via glucagon) on top of the appetite suppression achieved by dual agonists like tirzepatide. Phase 3 trial results reported in late 2025 showed 28.7% mean body weight loss at 68 weeks — the highest weight loss ever recorded in any Phase 3 obesity trial.
How It Works
GLP-1 receptor activation
Suppresses appetite via hypothalamic signalling, enhances glucose-dependent insulin secretion, and slows gastric emptying — the same mechanism that drives semaglutide's effectiveness.
GIP receptor activation
Potentiates insulin secretion, modulates fat distribution and adipose tissue function, and may improve gastrointestinal tolerability of the GLP-1 component — the same addition that distinguishes tirzepatide from semaglutide.
Glucagon receptor activation (the key differentiator)
This is what sets retatrutide apart from everything else. Glucagon receptor activation increases hepatic energy expenditure through fatty acid oxidation, promotes thermogenesis in adipose tissue, and reduces liver fat content. It effectively adds an 'energy output' mechanism on top of the 'energy input reduction' from GLP-1/GIP. The combined GLP-1/GIP activity counterbalances any blood sugar increase from glucagon, allowing net metabolic benefit.
Protocol Quick Reference
Benefits & Uses
- Record-breaking weight loss: Phase 3 trial (TRIUMPH-4) showed 28.7% mean body weight loss at the 12 mg dose over 68 weeks — the highest ever recorded in any Phase 3 obesity trial
- Dose-dependent response: Clear dose-response relationship: 26.4% at 9 mg and 28.7% at 12 mg, with 39.4% of participants on 12 mg losing 30%+ of body weight
- Liver fat reduction: The glucagon component drives significant liver fat reduction, with dedicated trials underway for metabolic-associated steatotic liver disease
- Joint pain improvement: TRIUMPH-4 showed approximately 75% reduction in knee osteoarthritis pain scores — a meaningful quality-of-life benefit beyond weight loss
- Blood pressure reduction: Systolic blood pressure reduced by 14.0 mmHg at the 12 mg dose
- Metabolic improvement: Favourable effects on blood sugar, HbA1c, lipid profiles, and insulin sensitivity across trials
Side Effects
Common
- Nausea — 43% at 12 mg dose, dose-dependent, most common during escalation
- Diarrhea — 33% at 12 mg dose
- Constipation — 25% at 12 mg dose
- Vomiting — 21% at 12 mg dose
- Decreased appetite
Less Common
- Dysesthesia (abnormal touch sensations) — a novel signal not seen with semaglutide or tirzepatide: 20.9% at 12 mg, 8.8% at 9 mg. Generally mild but requires monitoring
- Injection site reactions
- Fatigue
Serious
- Higher discontinuation rate than semaglutide or tirzepatide — 18.2% at 12 mg vs ~6-7% for other GLP-1 class compounds. Lower in patients with BMI 35+
- Pancreatitis risk (class warning for all incretin-based therapies)
- Thyroid C-cell concerns — avoid with personal/family history of medullary thyroid carcinoma
- Not recommended during pregnancy
- Long-term safety data beyond 68 weeks is limited as Phase 3 trials are ongoing
- As an investigational compound, individual response carries inherent uncertainty
Related Peptides
FAQ
Is retatrutide available in Thailand?▼
Research-grade retatrutide is available through peptide vendors serving the Thai market with domestic shipping. It is not available as an approved pharmaceutical product anywhere in the world yet. Phase 3 clinical trials are ongoing.
How does retatrutide compare to tirzepatide and semaglutide?▼
Retatrutide has produced the most weight loss of any compound in clinical trials: 28.7% in Phase 3 vs approximately 21% for tirzepatide and 15% for semaglutide. The key difference is the glucagon receptor component, which increases energy expenditure and fat burning beyond what the other compounds achieve.
Is retatrutide safe?▼
Phase 2 and 3 trial data showed a manageable safety profile broadly consistent with other incretin-based therapies, though with higher GI side effect rates and a novel dysesthesia signal (abnormal touch sensations in ~21% at 12 mg). Long-term data is limited. Medical supervision is strongly recommended.
When will retatrutide be officially approved?▼
Multiple Phase 3 trials are underway with results expected throughout 2026. If successful, regulatory approval could potentially come in 2027-2028. Until then, it is only available as a research-grade compound.
How much does retatrutide cost in Thailand?▼
Research-grade retatrutide pricing varies by vendor and vial size (5mg vs 10mg). Prices fluctuate with supply and demand. Check vendor websites directly for current rates and always verify purity testing before purchasing.
Disclaimer
This information is for educational purposes only and does not constitute medical advice. Peptides should be used under the guidance of a qualified healthcare professional. Individual results vary. Always consult your doctor before starting any peptide therapy.